HTG Molecular Diagnostics, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2019-11-15: Form 8-K; Period of report 2019-11-11; Description 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; Details 1.01.
- 2019-11-12: Form 8-K; Period of report 2019-11-12; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2019-10-07: Form 8-K; Period of report 2019-10-04; Description 8.01 Other Events.
- 2019-09-23: Form 8-K; Period of report 2019-09-20; Description 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events; Details 3.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2019-11-15 | 8-K | 2019-11-11 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. 1.02 On November 11, 2019, the Company and Cowen and Company, LLC mutually agreed to terminate that certain sales agreement between the parties dated March 13, 2019, effective immediately. | d833388d8k.htm |
| 2019-11-12 | 8-K | 2019-11-12 | 2.02 Results of Operations and Financial Condition | 2.02 On November 12, 2019, HTG Molecular Diagnostics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2019. | htgm-8k_20191112.htm |
| 2019-10-07 | 8-K | 2019-10-04 | 8.01 Other Events | htgm-8k_20191003.htm | |
| 2019-09-23 | 8-K | 2019-09-20 | 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 3.02 The disclosure regarding the pre-funded warrants set forth under the heading “Securities Purchase Agreement” under Item 8.01 of this report is incorporated by reference into this Item 3.02. 8.01 On September 20, 2019, we entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. (the “Underwriter”), relating to the issuance and sale in a public offering of 25,476,989 shares of our common stock, par value $0.001 per share. | d804559d8k.htm |
| 2019-09-19 | 8-K | 2019-09-19 | 8.01 Other Events | 8.01 On September 19, 2019, we filed with the Securities and Exchange Commission (the “SEC”) a preliminary prospectus supplement in connection with a proposed public offering of shares of our common stock. | d805196d8k.htm |
| 2019-08-20 | 8-K | 2019-08-14 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On August 14, 2019, HTG Molecular Diagnostics, Inc. (the “Company”) held its 2019 Annual Meeting of Stockholders (the “Annual Meeting”). | htgm-8k_20190814.htm |
| 2019-08-06 | 8-K | 2019-08-06 | 2.02 Results of Operations and Financial Condition | 2.02 On August 6, 2019, HTG Molecular Diagnostics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2019. | htgm-8k_20190806.htm |
| 2019-06-14 | 8-K | 2019-06-14 | 8.01 Other Events | htgm-8k_20190614.htm | |
| 2019-05-28 | 8-K | 2019-05-23 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On May 23, 2019, our board of directors appointed Laura Godlewski as our principal accounting officer, effective immediately, replacing Shaun D. McMeans, our Senior Vice President and Chief Financial Officer, in that capacity. | htgm-8k_20190523.htm |
| 2019-05-09 | 8-K | 2019-05-09 | 2.02 Results of Operations and Financial Condition | 2.02 On May 9, 2019, HTG Molecular Diagnostics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2019. | htgm-8k_20190509.htm |
| 2019-04-29 | 8-K | 2019-04-23 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | htgm-8k_20190423.htm |
| 2019-04-02 | 8-K | 2019-03-28 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 28, 2019, the Board of Directors (the “Board”) of HTG Molecular Diagnostics, Inc. (the “Company”) appointed John L. Lubniewski as a member of the Board, effective immediately. | htgm-8k_20190328.htm |
| 2019-03-13 | 8-K | 2019-03-13 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d721425d8k.htm |
| 2019-03-07 | 8-K | 2019-03-07 | 2.02 Results of Operations and Financial Condition | 2.02 On March 7, 2019, HTG Molecular Diagnostics, Inc. issued a press release announcing its financial results for the year ended December 31, 2018. | htgm-8k_20190307.htm |
| 2019-02-20 | 8-K | 2019-02-15 | 8.01 Other Events | 8.01 On February 15, 2019, HTG Molecular Diagnostics, Inc. (the “Company”) and QIAGEN Manchester Limited (“QML”), a U.K. corporation and wholly owned subsidiary of QIAGEN N.V., entered a fourth amendment of the second statement of work (“SOW Two”) under the parties’ Master Assay Development, Commercialization and Manufacturing Agreement, effective as of February 5, 2019 (such amendment, the “Fourth SOW Two Amendment”). | htgm-8k_20190215.htm |
| 2019-01-30 | 8-K | 2019-01-24 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 As previously reported, on January 14, 2019 our Board of Directors (the “Board”) appointed John L. Lubniewski as our Chief Executive Officer and designated Timothy B. Johnson as Executive Chairman of the Board, each effective March 31, 2019 (the “Effective Date”). | htgm-8k_20190124.htm |
| 2019-01-14 | 8-K | 2019-01-14 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 14, 2019, Timothy B. Johnson resigned from his position as our Chief Executive Officer, effective March 31, 2019 (the “Effective Date”), and our board of directors (the “Board”) appointed John L. Lubniewski as our Chief Executive Officer, to be effective as of the Effective Date. | d611134d8k.htm |
| 2019-01-07 | 8-K | 2019-01-07 | 2.02 Results of Operations and Financial Condition | 2.02 On January 7, 2019, HTG Molecular Diagnostics, Inc. issued a press release announcing certain preliminary financial results as of and for the full year ended December 31, 2018. | htgm-8k_20190107.htm |